Ensuring sustained incentives for pharma to develop medicine for the poor

Published by the Access to Medicine Foundation

This article details how pharma companies engage with the Product Development Partnership (PDP) model and other models that are based on the combined principles of open collaboration and access to medicine.

A commentary exploring the progress made by major pharmaceutical companies in collaborating to innovate products for diseases of poverty, and the success of R&D models in incentivising these contributions, by Clarke B. Cole and Jayasree K. Iyer. 

Sign up to receive updates about our work.